Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

Moderate to Severe Psoriasis Clinical Trial

Official title:
Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

Status Terminated

Clinical Trial Summary

Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with the use of adalimumab in participants with chronic plaque psoriasis complying with the dosing and monitoring recommendations of the local approved label.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01156532
Study type	Observational
Source	AbbVie
Contact
Status	Terminated
Phase	N/A
Start date	November 2010
Completion date	August 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00678470` - Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis	N/A
Completed	`NCT00256139` - CLEAR Study: Clinical Experience Acquired With Raptiva Study	Phase 3
Completed	`NCT00936065` - Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis	Phase 4
Completed	`NCT00442650` - Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis	Phase 3
Completed	`NCT05344248` - Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing	Phase 1/Phase 2
Completed	`NCT03051217` - A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis	Phase 2/Phase 3